AP1584A - Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis. - Google Patents

Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis.

Info

Publication number
AP1584A
AP1584A APAP/P/2001/002182A AP2001002182A AP1584A AP 1584 A AP1584 A AP 1584A AP 2001002182 A AP2001002182 A AP 2001002182A AP 1584 A AP1584 A AP 1584A
Authority
AP
ARIPO
Prior art keywords
compounds
treatment
malaria
metabolites
precursors
Prior art date
Application number
APAP/P/2001/002182A
Other versions
AP2001002182A0 (en
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T Prendergast
Original Assignee
Hollis Eden Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals Inc filed Critical Hollis Eden Pharmaceuticals Inc
Publication of AP2001002182A0 publication Critical patent/AP2001002182A0/en
Application granted granted Critical
Publication of AP1584A publication Critical patent/AP1584A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention provides the use of 17-ketosteroid compounds, as well as derivatives, metabolites and precursors of such compounds, and pharmaceutically acceptable salts of any of these compounds, collectively defined herein as the "compounds of the present invention", in the treatment of malaria, African Trypanosomiasis and American Trypanosomiasis, or to ameliorate or reduce one or more symptoms associated with a Plasmodium or Trypanosoma infection. The present invention is further directed to the use of such compounds in the treatment or prevention of one or more kind of parasites and/or one or more diseases caused by such parasites, against one or more kind of Mycoplasma and/or one or more diseases caused by such Mycoplasmas and/or against one or more of the following indication or infections a) hairy Leukoplakia, (b) oral candidosis, (c) mouth ulcerations-aphthous/herpetic/bacterial, (d) fungal Candida, (e) human papilloma virus, (f) molluscum contagiosum, (g) squamous oral carcinoma, (h) Kapos's sarcoma oral lesions, (I) peridontitis, (j) necrotizing gingivitis, (k) orafacial herpes zoster, and (i) rotaviruses, as well as all other indications and infections. The compounds of the present invention may also be used to ameliorate or reduce one of more symptoms associated with any infection or condition disclosed herein.
APAP/P/2001/002182A 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis. AP1584A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10992398P 1998-11-24 1998-11-24
US12408799P 1999-03-11 1999-03-11
US12605699P 1999-03-23 1999-03-23
PCT/US1999/028079 WO2000032201A2 (en) 1998-11-24 1999-11-24 Use of 17-ketosteroids for the treatment of malaria and trypanosomiasis

Publications (2)

Publication Number Publication Date
AP2001002182A0 AP2001002182A0 (en) 2001-06-30
AP1584A true AP1584A (en) 2006-03-01

Family

ID=27380739

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002182A AP1584A (en) 1998-11-24 1999-11-24 Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis.

Country Status (13)

Country Link
EP (1) EP1135138A2 (en)
JP (1) JP2002531407A (en)
KR (2) KR20070004149A (en)
CN (1) CN1348373A (en)
AP (1) AP1584A (en)
AU (2) AU776853B2 (en)
BR (1) BR9915623A (en)
CA (1) CA2356539A1 (en)
HK (1) HK1043319A1 (en)
IL (1) IL142941A0 (en)
NZ (1) NZ511720A (en)
OA (1) OA11715A (en)
WO (1) WO2000032201A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20070129282A1 (en) 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US6555523B1 (en) 1999-07-08 2003-04-29 Patrick T. Prendergast Use of cirsiliol and derivatives to treat infections
CA2669753C (en) * 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US7910755B2 (en) 2004-09-29 2011-03-22 Harbor Biosciences, Inc. Stem cell expansion and uses
US8217025B2 (en) 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
KR100786126B1 (en) * 2007-08-14 2007-12-18 주식회사 아바코 A scribe head device and scribe method for maintaining the flatness of the cutting object by a non-contact method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956355A (en) * 1987-04-16 1990-09-11 Colthurst Limited Agents for the arrest and therapy of retroviral infections
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956355A (en) * 1987-04-16 1990-09-11 Colthurst Limited Agents for the arrest and therapy of retroviral infections
WO1997038695A1 (en) * 1996-04-17 1997-10-23 Prendergast Patrick T Dhea combination therapy
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors

Also Published As

Publication number Publication date
NZ511720A (en) 2002-12-20
HK1043319A1 (en) 2002-09-13
AU2004237812B2 (en) 2007-11-29
BR9915623A (en) 2001-08-14
WO2000032201A3 (en) 2000-12-21
IL142941A0 (en) 2002-04-21
KR20070004149A (en) 2007-01-05
CA2356539A1 (en) 2000-06-08
AU2004237812A1 (en) 2005-01-13
AP2001002182A0 (en) 2001-06-30
OA11715A (en) 2005-03-14
CN1348373A (en) 2002-05-08
AU776853B2 (en) 2004-09-23
AU1745300A (en) 2000-06-19
WO2000032201A2 (en) 2000-06-08
KR20010101073A (en) 2001-11-14
EP1135138A2 (en) 2001-09-26
JP2002531407A (en) 2002-09-24

Similar Documents

Publication Publication Date Title
HUP0102879A2 (en) Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome
MY129552A (en) Solid oral dosage form comprising a combination of metformin and glibenclamide
NL980018I2 (en) Antiviral combinations containing nucleoside analogues.
HUP0104573A2 (en) Agrochemical formulations
AP1584A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis.
PT979244E (en) CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
EP0299602A3 (en) Use of indolone derivatives for the treatment of parkinsons disease
ATE189400T1 (en) BONE GROWTH-PROMOTING COMPOSITION
CY1110988T1 (en) HIGHLY DETERMINED SOLID PREPARATION
CA2402336A1 (en) Concentrated solutions of carvedilol
CA2135614A1 (en) Use of urodilatin in pulmonary and bronchial diseases
ITMI911155A1 (en) HIGH VISCOSITY AND LOW PEROXIDE OXYGEN PERFLUOROPOLYETERS, AND PROCEDURE FOR THEIR PREPARATION
IE53460B1 (en) Antiviral alpha,alpha-dialkyl admantylethylamines
ES2074946A1 (en) NEW COMPOUNDS DERIVED FROM 1,2-ETHANODIAMINE-N, N, N ', N'-TETRAS-SUBSTITUTED.
CA2077693A1 (en) Use of ketorolac for treatment of periodontal disease
AU6214101A (en) Use of cdp-choline for the treatment of alcohol withdrawal syndrome
CA2219678A1 (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases
MD1473F2 (en) Antiherpetic remedy
HUP9800715A2 (en) Injury and mucous membrane antiseptics containing magnesium perphthalate
IT1270008B (en) PURINIC AND 8-AZAPURINIC DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF AIDS
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
CA2099667A1 (en) Agent for treating hepatic diseases
PL371012A1 (en) Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease
CA2039643A1 (en) Anti-wart composition
Bandyopadhyay et al. AIDS and the gateway of the body